Gemcitabine and carboplatin treatment in Patients with relapsing ovarian cancer

Neoplasma

Volumn 56, Issue 4, 2009, Pages 291-297

  Sufliarsky, J ^a   Chovanec, J ^b   Svetlovska, D ^a   Minarik, T ^a   Packan, T ^c   Kroslakova, D ^d   Lalabova, R ^e   Helpianska, L ^f   Horvathova, D ^g   Sevcik, L ^h   Spacek, J ⁱ   Laluha, A ^j   Tkacova, V ^k   Malec, V ^l   Rakicka, G ^l   Magdin, D ^m   Jancokova, I ^m   Dorr, A ^e   Stresko, M ^d   Habetinek, V ⁿ   Koza, I ^a   more..

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b Teaching Hospital Brno   (Czech Republic)

^c East Slovakian Museum   (Slovakia)

^d Teaching Hospital   (Slovakia)

^e Masaryk's Institute of Oncology Brno   (Slovakia)

^f St Elizabeth's Institute of Oncology   (Czech Republic)

^g Teaching Hospital with an Outpatient Clinic Nové Zámky   (Czech Republic)

^h Teaching Hospital   (Czech Republic)

ⁱ UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^j St Lucas' Hospital with an Outpatient Clinic   (Czech Republic)

^k Teaching Hospital in Pre ov   (Czech Republic)

^l Hospital with an Outpatient Clinic Banská   (Czech Republic)

^m Hospital with an Outpatient Clinic Bojnice   (Czech Republic)

ⁿ Eli Lilly Czech Republic   (Czech Republic)

more..

Author keywords

Carboplatin; Gemcitabine; Relapsing ovarian cancer; Second line treatment

Indexed keywords

CARBOPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; PLATINUM; TOPOTECAN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FISHER EXACT TEST; FLU LIKE SYNDROME; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; LIVER TOXICITY; LOG RANK TEST; LUNG DISEASE; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TUMOR GROWTH; X RAY; CLINICAL TRIAL; COLLOID CARCINOMA; CYSTADENOCARCINOMA; DISEASE COURSE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DEOXYCYTIDINE; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68149103336     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_04_291     Document Type: Article

References (34)

1. Health statistics yearbook of the Slovak Republic 2005, Bratislava: National Health Information Centre, 2006.
2. Cancer Incidence 2004 in the Czech Republic, Praha: Institute of Health Information and Statistics of the Czech Republic and National Oncologic Registry, 2007.
3. McGuire WP, Hoskins WJ, Brady MF, et al. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: A Gynecologic Oncology Group Study. Semin Oncol 1997; 24 (Suppl 2): 13-16.
4. Du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first- -line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
5. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gyncologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200. doi:10.1200/JCO.2003.02.153
6. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393.
7. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36: 207-211. doi:10.1016/0090-8258(90)90174-J
8. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum- -based chemotherapy in women with relapsed ovarian cancer: The ICON4/ AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106. doi:10.1016/S0140-6736(03)13718-X
9. Armstrong DK. Relapsed ovarian cancer: Challenges and management strategies for a chronic disease. Oncologist 2002; 7(suppl 5): 20-28. doi:10.1634/theoncologist.7-suppl-5-20
10. Markman M, Webster K, Zanotti K, et al. Phase 2 trial of single- -agent gemcitabine in platinum/paclitaxel refractory ovarian cancer. Gynecol Oncol 2003; 90: 593-596. doi:10.1016/S0090- 8258(03)00399-408
11. Von Minckwitz G, Bauknecht T, Visseren-Grul CM, et al. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999; 10: 853-855. doi:10.1023/A: 1008364327684
12. Friedlander M, Millward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998; 9: 1343-1345. doi:10.1023/A:1008469212268
13. D'Agostino G, Amant F, Berteloot P, et al. Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003; 88: 266-269. doi:10.1016/ S0090-8258(03)00011-18
14. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89-93. doi:10.1006/gyno.1996.0284
15. Bilgin T, Ozalp S, Yalçin O, et al. Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients. Eur J Gynaecol Oncol 2003; 24(2): 169-170.
16. Gebauer G, Jager W, Lang N. Gemcitabine (Gemzar) chemotherapy in heavily pre-treated patients with recurrent ovarian cancer. J Cancer Res Clin Oncol 1999; 125(SUPPL.): S88.
17. Safra T, Ron I, Boaz M, et al. Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients. Acta Oncol 2006; 45: 463-468. doi:10.1080/02841860500509035
18. Piura B, Rabinovich A. Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma. Eur J Gynaecol Oncol 2004; 25: 449-452.
19. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86:1530-1533. doi:10.1093/jnci/86.20.1530
20. Nogue M, Cirera L, Arcusa A, et al. Phase II study of gemcitabine and cisplatin in chemonaïve patients with advanced epithelial ovarian cancer. Anticancer Drugs 2002; 13: 839-845. doi:10.1097/00001813-200209000-00009
21. Bauknecht T, Hefti A, Morack G, et al. Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. Int J Gynecol Cancer 2003; 13: 130-137. doi:10.1046/j.1525- 1438.2003.13039.x
22. Belpomme D, Krakowski I, Beauduin M, et al. Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study. Gynecol Oncol 2003; 91: 32-38. doi:10.1016/S0090-8258(03)00413-X
23. Shaharyar, Shami N, Mahmood I, et al. A phase II trial of gemcitabine and Cisplatin combination chemotherapy in advanced epithelial ovarian cancer with bulky residual disease. Proc Am Soc Clin Oncol 2002; 21: A2518.
24. Gallardo D, Calderillo G, Serrano A, et al. A phase II study of gemcitabine plus cisplatin in previously untreated advanced ovarian cancer. Anticancer Res 2006; 26: 3137-3141.
25. Suprasert P, Srisomboon J, Phongnarisorn C, et al. A prospective phase II study of gemcitabine-cisplatin as first-line chemotherapy in advanced epithelial ovarian and fallopian tube cancer. Proc Am Soc Clin Oncol 2003; 22: 457(A1917).
26. Rose PG, Mossbruger K, Fusco N, et al. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003; 88: 17-21. doi:10.1006/gyno.2002.6850
27. Nagourney RA, Brewer CA, Radecki S, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2003; 88: 35-39. doi:10.1006/gyno.2002.6855
28. Efstathiou E. Preliminary results of a phase II study of the combination of biweekly cisplatin (CDDP) and gemcitabine in patients with platinum refractory advanced ovarian carcinoma. Ann Oncol 2004; 15(Suppl. 3): A489P.
29. Kunkel LM, Evans SS, Dottino PR, et al. Cisplatin & gemcitabine in relapsed ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: A1379.
30. Papadimitriou CA, Fountzilas G, Aravantinos G, et al. Second- -line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group Study. Gynecol Oncol 2004; 92: 152-159. doi:10.1016/j.ygyno.2003.09.021
31. Kose MF, Sufliarsky J, Beslija S, et al. A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma. Gynecol Oncol 2005; 96: 374-380. doi:10.1016/ j.ygyno.2004.10.011
32. Orlando M, Nadal J, Chacon R. Gemcitabine (G) and carboplatin (C) in patients (pts) with relapsed ovarian cancer (ROC): A phase I-II study. Proc Am Soc Clin Oncol 2000; A1594.
33. Du Bois A, Luck HJ, Pfisterer J, et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose- finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) ovarian cancer study group. Ann Oncol 2001; 12: 1115-1120. doi:10.1023/A:1011605008922
34. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO- -OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-4707. doi:10.1200/JCO.2006.06.0913